Based in Austin, Texas, Checkpoint Capital specializes in providing transparent pricing and technology solutions tailored for portfolio management within the financial services sector. Their offerings are designed to empower community banks to oversee investment portfolios with the same degree of sophistication and cost-effectiveness as larger institutions.
Mr. Sam Huang, Managing Partner at Checkpoint Capital, previously held positions as an Analyst at BVF Partners and served as a Board Observer at Nimbus Therapeutics & Dren Bio and a Board Member at Elektrofi. Before joining BVF Partners L.P. in 2018, he worked with J.P. Morgan's Healthcare Investment Banking team and co-founded a life-sciences-focused MIT alumni angel group. Mr. Huang holds a B.S. in Chemical Engineering from the Massachusetts Institute of Technology.
Checkpoint Capital disclosed $165,097,477 in managed 13F securities in their Q4 2023 filing. Their top 10 holdings accounted for 90.27% of their portfolio, with Rhythm Pharmaceuticals Inc. being their largest holding, with 730,000 shares held.
